Skip to main content
Signal8

BioCorRx Inc. (BICX) Form 10-Q — Nov 16, 2026

$BICXForm 10-QFiled Nov 16, 2026, 6:02 AM ET0001477932-26-006955Original filing

BioCorRx filed its Q3 2026 10-Q with an explicit going-concern warning: cash was just $18,233 against a working capital deficit of $8,652,785, and management says substantial…

Key figures

Total Debt
$1,254,384 notes payable plus $847,763 related-party notes; working capital deficit of $8,652,785
Revenue Yoy
-81.7% (three months: -40,348 vs 213,910)
Cash Position
18233
Shares Outstanding
30524083
Shares issued yoy
30,524,083 vs 24,489,311 at Dec 31, 2025 (~25% increase)
Rd expense nine months
1810781
Grant income nine months
1810748

AI analysis

Red flags6 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    BioCorRx Inc. (BICX) Form 10-Q — Nov 16, 2026: AI Analysis | Signal8